A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease  

Oleh:

Catassi, Carlo ; Fabiani, Elisabetta ; Iacono, Giuseppe ; D'Agate, Cinzia ; Francavilla, Ruggiero ; Biagi, Federico ; Volta, Umberto ; Accomando, Salvatore ; Picarelli, Antonio ; Vitis, Italo De ; Pianelli, Giovanna ; Gesuita, Rosaria ; Carle, Flavia ; Mandolesi, Alessandra ; Bearzi, Italo ; Fasano, Alessio

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The American Journal of Clinical Nutrition vol. 85 no. 01 (Jan. 2007), page 160.
Topik: Gastroenterology • celiac disease • gluten toxicity • small-intestinal morphometry • gluten-free diet • gluten threshold in gluten-free food

Ketersediaan

Perpustakaan FK Nomor Panggil: A07.K.2007.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

1 From the Center For Celiac Research, University of Maryland School of Medicine, Baltimore, MD (CC and AF); the Department of Pediatrics, Università Politecnica delle Marche, Ancona, Italy (CC, EF, and GP); the Department of Gastroenterology, Children Hospital, Palermo, Italy (GI); the University Department of Gastroenterology, Catania, Italy (CD); the University Department of Pediatrics, Bari, Italy (RF); the University Department of Gastroenterology, Pavia, Italy (FB); the University Department of Internal Medicine, Bologna, Italy (UV); the University Department of Pediatrics, Palermo, Italy (SA); the Department of Gastroenterology, "La Sapienza" University, Rome, Italy (AP); the Gastroenterology Unit, Catholic University of Sacred Heart, Rome, Italy (ID); the Department of Biostatistics, Università Politecnica delle Marche, Ancona, Italy (RG and FC); the Department of Pathology, Università Politecnica delle Marche, Ancona, Italy (AM and IB). Background: Treatment of celiac disease (CD) is based on the avoidance of gluten-containing food. However, it is not known whether trace amounts of gluten are harmful to treated patients. Objective: The objective was to establish the safety threshold of prolonged exposure to trace amounts of gluten (ie, contaminating gluten). Design: This was a multicenter, double-blind, placebo-controlled, randomized trial in 49 adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for 2 y. The background daily gluten intake was maintained at <5 mg. After a baseline evaluation (t0), patients were assigned to ingest daily for 90 d a capsule containing 0, 10, or 50 mg gluten. Clinical, serologic, and histologic evaluations of the small intestine were performed at t0 and after the gluten microchallenge (t1). Results: At t0, the median villous height/crypt depth (Vh/Cd) in the small-intestinal mucosa was significantly lower and the intraepithelial lymphocyte (IEL) count (x 100 enterocytes) significantly higher in the CD patients (Vh/Cd: 2.20; 95% CI: 2.11, 2.89; IEL: 27; 95% CI: 23, 34) than in 20 non-CD control subjects (Vh/Cd: 2.87; 95% CI: 2.50, 3.09; IEL: 22; 95% CI: 18, 24). One patient (challenged with 10 mg gluten) developed a clinical relapse. At t1, the percentage change in Vh/Cd was 9% (95% CI: 3%, 15%) in the placebo group (n = 13), –1% (–18%, 68%) in the 10-mg group (n = 13), and –20% (–22%, –13%) in the 50-mg group (n = 13). No significant differences in the IEL count were found between the 3 groups. Conclusions: The ingestion of contaminating gluten should be kept lower than 50 mg/d in the treatment of CD.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali